Fig. 5

Fig. 5 Fig. 5. NATx0 reduces glucose intolerance in a mouse model of diet-induced obesity. C57BL/6 mice were treated orally with NATx0 (150 mg/kg) or vehicle for 4 weeks under normal rodent chow diet. After, animals were fed with high fat diet (HFD) and treated orally with NATx0 (150 mg/kg) or vehicle for another 11 weeks. A, Graph shows animal weight evolution during the course of the experiment. At week 4, mice started to ate HFD. B, At week 12, consumed water, diuresis, feces and food intake parameters were measured in metabolic cages within 24 h in NATx0 treated or vehicle treated mice. Two-tailed unpaired t-test: ns > 0.25. C, Glucose tolerance test (GTT) was performed by i.p injection of 1.5 g/kg body weight of glucose solution to fasted mice and plasma glucose was measured in blood before and after 15, 30, 60, and 120 min of the injection. Two-tailed unpaired t-test: ** = 0.0031. Inset shows calculated area under the curve (AUC) for NATx0 or vehicle treated mice glucose response. Two-tailed unpaired t-test: * = 0.0319. D, At the end of the experiment, mice were injected with 0.5 U/kg body weight of insulin and sacrificed to obtain muscle. Western blot analysis was performed to analyze p-Akt, Akt and IL-1β protein expression in muscle. Two-tailed unpaired t-test: vehicle vs. NATx0 * = 0.0147 for p-Akt/Akt and * = 0.0131 for pro-IL-1β/IL-1β.